Shih-Wei Lai1,2, Cheng-Li Lin3,4, Kuan-Fu Liao5,6,7. 1. College of Medicine, China Medical University, Taichung City, Taiwan. wei@mail.cmuh.org.tw. 2. Department of Family Medicine, China Medical University Hospital, Taichung City, Taiwan. wei@mail.cmuh.org.tw. 3. College of Medicine, China Medical University, Taichung City, Taiwan. orangechengli@gmail.com. 4. Management Office for Health Data, China Medical University Hospital, Taichung City, Taiwan. orangechengli@gmail.com. 5. College of Medicine, Tzu Chi University, Hualien City, Taiwan. kuanfuliaog@gmail.com. 6. Department of Internal Medicine, Taichung Tzu Chi General Hospital, No. 66, Sec. 1, Fongsing Road, Tanzi District, Taichung City, 427, Taiwan. kuanfuliaog@gmail.com. 7. Graduate Institute of Integrated Medicine, China Medical University, Taichung City, Taiwan. kuanfuliaog@gmail.com.
Abstract
BACKGROUND AND OBJECTIVE: No sufficient research has focused on the relationship between meloxicam use and acute pancreatitis. This study aimed to explore this issue in Taiwan. METHODS: This case-control study was conducted using the database of the Taiwan National Health Insurance Program. In all, there were 6780 cases aged 20-84 years who were newly diagnosed with acute pancreatitis during the period 1998-2011, and 21,393 control subjects without acute pancreatitis. Cases and controls were matched for sex, age and comorbidities. Odds ratios (ORs) and 95% confidence intervals (CIs) were measured to explore the associations between acute pancreatitis, meloxicam use and comorbidities, using a multivariable unconditional logistic regression model. RESULTS: After controlling for potential confounding factors, the adjusted OR for acute pancreatitis was 1.76 (95% CI 1.30-2.40) for subjects with current use of meloxicam, in comparison with subjects who had never used meloxicam. The adjusted OR decreased to 1.29 (95% CI 0.82-2.03) for subjects with late use of meloxicam, but without statistical significance. CONCLUSIONS: Current use of meloxicam is associated with increased odds of acute pancreatitis. Clinicians should consider the potential risk of acute pancreatitis when prescribing meloxicam.
BACKGROUND AND OBJECTIVE: No sufficient research has focused on the relationship between meloxicam use and acute pancreatitis. This study aimed to explore this issue in Taiwan. METHODS: This case-control study was conducted using the database of the Taiwan National Health Insurance Program. In all, there were 6780 cases aged 20-84 years who were newly diagnosed with acute pancreatitis during the period 1998-2011, and 21,393 control subjects without acute pancreatitis. Cases and controls were matched for sex, age and comorbidities. Odds ratios (ORs) and 95% confidence intervals (CIs) were measured to explore the associations between acute pancreatitis, meloxicam use and comorbidities, using a multivariable unconditional logistic regression model. RESULTS: After controlling for potential confounding factors, the adjusted OR for acute pancreatitis was 1.76 (95% CI 1.30-2.40) for subjects with current use of meloxicam, in comparison with subjects who had never used meloxicam. The adjusted OR decreased to 1.29 (95% CI 0.82-2.03) for subjects with late use of meloxicam, but without statistical significance. CONCLUSIONS: Current use of meloxicam is associated with increased odds of acute pancreatitis. Clinicians should consider the potential risk of acute pancreatitis when prescribing meloxicam.
Authors: Claudia Nitsche; Sandrina Maertin; Jonas Scheiber; Christoph A Ritter; Markus M Lerch; Julia Mayerle Journal: Curr Gastroenterol Rep Date: 2012-04
Authors: H T Sørensen; J Jacobsen; M Nørgaard; L Pedersen; S P Johnsen; J A Baron Journal: Aliment Pharmacol Ther Date: 2006-07-01 Impact factor: 8.171